Genomic approaches in the management and treatment of breast cancer

被引:26
作者
Chang, JC [1 ]
Hilsenbeck, SG [1 ]
Fuqua, SAW [1 ]
机构
[1] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
关键词
microarrays; breast; prediction response; prognosis;
D O I
10.1038/sj.bjc.6602410
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most common malignancy afflicting women from Western cultures. It has been estimated that approximately 211 000 women will be diagnosed with breast cancer in 2003 in the United States alone, and each year over 40 000 women will die of this disease. Developments in breast cancer molecular and cellular biology research have brought us closer to understanding the genetic basis of this disease. Unfortunately, this information has not yet been incorporated into the routine diagnosis and treatment of breast cancer in the clinic. Recent advancements in microarray technology hold the promise of further increasing our understanding of the complexity and heterogeneity of this disease, and providing new avenues for the prognostication and prediction of breast cancer outcomes. The most recent application of microarray genomic technologies to studying breast cancer will be the focus of this review.
引用
收藏
页码:618 / 624
页数:7
相关论文
共 34 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]  
Adeyinka A, 2002, CLIN CANCER RES, V8, P3788
[3]   A faithful method for PCR-mediated global mRNA amplification and its integration into microarray analysis on laser-captured cells [J].
Aoyagi, K ;
Tatsuta, T ;
Nishigaki, M ;
Akimoto, S ;
Tanabe, C ;
Omoto, Y ;
Hayashi, S ;
Sakamoto, H ;
Sakamoto, M ;
Yoshida, T ;
Terada, M ;
Sasaki, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 300 (04) :915-920
[4]   Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].
Ayers, M ;
Symmans, WF ;
Stec, J ;
Damokosh, AI ;
Clark, E ;
Hess, K ;
Lecocke, M ;
Metivier, J ;
Booser, D ;
Ibrahim, N ;
Valero, V ;
Royce, M ;
Arun, B ;
Whitman, G ;
Ross, J ;
Sneige, N ;
Hortobagyi, GN ;
Pusztai, L .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293
[5]   Global gene expression changes during neoadjuvant chemotherapy for human breast cancer [J].
Buchholz, TA ;
Stivers, DN ;
Stec, J ;
Ayers, M ;
Clark, E ;
Bolt, A ;
Sahin, AA ;
Symmans, WF ;
Hess, KR ;
Kuerer, HM ;
Valero, V ;
Hortobagyi, GN ;
Pusztai, L .
CANCER JOURNAL, 2002, 8 (06) :461-468
[6]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[7]  
2-H
[8]   Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer [J].
Chang, J ;
Powles, TJ ;
Allred, DC ;
Ashey, SE ;
Clark, GM ;
Makris, A ;
Assersohn, L ;
Gregory, RK ;
Osborne, CK ;
Dowsett, M .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3058-3063
[9]   Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [J].
Chang, JC ;
Wooten, EC ;
Tsimelzon, A ;
Hilsenbeck, SG ;
Gutierrez, MC ;
Elledge, R ;
Mohsin, S ;
Osborne, CK ;
Chamness, GC ;
Allred, DC ;
O'Connell, P .
LANCET, 2003, 362 (9381) :362-369
[10]   PREDICTION OF RELAPSE OR SURVIVAL IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER BY DNA FLOW-CYTOMETRY [J].
CLARK, GM ;
DRESSLER, LG ;
OWENS, MA ;
POUNDS, G ;
OLDAKER, T ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (10) :627-633